WO2018117345A1 - Induction sélective de l'apoptose du cancer par inhibition combinée du glutathion, de la thiorédoxine et de l'antioxydant nrf2 - Google Patents

Induction sélective de l'apoptose du cancer par inhibition combinée du glutathion, de la thiorédoxine et de l'antioxydant nrf2 Download PDF

Info

Publication number
WO2018117345A1
WO2018117345A1 PCT/KR2017/004963 KR2017004963W WO2018117345A1 WO 2018117345 A1 WO2018117345 A1 WO 2018117345A1 KR 2017004963 W KR2017004963 W KR 2017004963W WO 2018117345 A1 WO2018117345 A1 WO 2018117345A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
gene
seq
thioredoxin
glutathione
Prior art date
Application number
PCT/KR2017/004963
Other languages
English (en)
Korean (ko)
Inventor
노종렬
Original Assignee
울산대학교 산학협력단
재단법인 아산사회복지재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 울산대학교 산학협력단, 재단법인 아산사회복지재단 filed Critical 울산대학교 산학협력단
Publication of WO2018117345A1 publication Critical patent/WO2018117345A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a composition for the prevention or treatment of cancer comprising glutathione, thioredoxin and Nrf2 expression inhibitor or activity inhibitor as an active ingredient.
  • Head and neck cancer is a cancer that occurs in tissues such as the nasal cavity, pharynx, larynx, salivary glands, and thyroid gland, and the incidence of cancer worldwide accounts for about 5% of all malignancies.
  • cisplatin the most powerful anticancer agent currently used in clinical practice, is used for the treatment of head and neck cancer.
  • cisplatin is a very effective anticancer agent against various types of cancer, recent studies show that clinical problems are increasing due to its resistance. Therefore, various studies have recently been conducted to treat cancers that become cisplatin resistant using proteins and genes of cancer cells that induce resistance to cisplatin.
  • the increased amount of oxidative stress in cancer cells is due to an imbalance between the production and elimination of reactive oxygen species (Toyokuni S, Okamoto K, Yodoi J, Hiai H. FEBS Lett 358: 1-3, 1995). Sustained oxidative stress in cancer partially explains why cancer cells have different characteristics from those of normal cells susceptible to ROS damage (Trachootham D, Alexandre J, Huang P. Nat Rev Drug Discov). 8: 579-91, 2009). To process the oxidation-reduction state of imbalance, cancer cells corresponds to the free radical scavenging system, elevated high ROS amount (Diehn M et al, Nature 458 :. 780-3, 2009).
  • Intracellular antioxidant GSH has been reported to be synthesized by GCL (glutamate cysteine ligase) with GCLM (glutamate cysteine ligase modifier) and GCLC (glutamate cysteine ligase catalytic) subunits
  • GCL glutamate cysteine ligase
  • GCLM glutamate cysteine ligase modifier
  • GCLC glutamate cysteine ligase catalytic subunits
  • Nrf2 is a transcription factor that binds to the antioxidant responsive element (ARE) and plays an important role in regulating the homeostasis of redox within cells (Hayes JD, Dinkova-Kostova AT. Trends Biochem Sci 39: 199-218, 2014).
  • ARE antioxidant responsive element
  • cancer cells are known to compensate for stress caused by the amount of intracellular ROS by actively up-regulating various antioxidant pathways that contribute to tumor progression (DeNicola GM et al., Nature 475: 106-9, 2011; Diehn M et al. , Nature 458: 780-3, 2009; and Schafer ZT et al., Nature 461: 109-13, 2009).
  • An object of the present invention is a pharmaceutical for the prevention or treatment of cancer comprising glutathione, thioredoxin, and Nrf2 (nuclear factor (erythroid-derived 2) -like 2) as an active ingredient. It is to provide a composition.
  • Another object of the present invention is the step of (a) treating the test substance to cancer cells; (b) confirming that the expression levels of glutathione, thioredoxin, and Nrf2 (nuclear factor (erythroid-derived 2) -like 2) mRNA expression levels or proteins are suppressed. It is to provide a screening method.
  • preventing or treating cancer comprising an activity inhibitor of a protein of at least one gene selected from the group consisting of glutathione, thioredoxin and Nrf2 (nuclear factor (erythroid-derived 2) -like 2) It provides a pharmaceutical composition.
  • (ii) may be a pharmaceutical composition for the prevention or treatment of cancer comprising glutathione, thioredoxin and Nrf2 (nuclear factor (erythroid-derived 2) -like 2) inhibitory activity of the protein of the gene of the gene .
  • Nrf2 nuclear factor (erythroid-derived 2) -like 2) inhibitory activity of the protein of the gene of the gene .
  • glutathione Glutathione
  • Thioredoxin thioredoxin
  • Nrf2 nuclear factor (erythroid-derived 2) -like 2)
  • It may be a pharmaceutical composition for the prevention or treatment of cancer, including an inhibitor that simultaneously inhibits the expression of thioredoxin and Nrf2 gene and glutathione gene expression inhibitor.
  • it may be a pharmaceutical composition for the prevention or treatment of cancer, including an inhibitor that simultaneously inhibits expression of glutathione, thioredoxin and Nrf2 gene.
  • glutathione Glutathione
  • Thioredoxin thioredoxin
  • Nrf2 nuclear factor (erythroid-derived 2) -like 2)
  • It may be a pharmaceutical composition for preventing or treating cancer, including an inhibitor that simultaneously inhibits protein activity of thioredoxin and Nrf2 gene and a protein activity inhibitor of glutathione gene.
  • it may be a pharmaceutical composition for the prevention or treatment of cancer, including inhibitors that simultaneously inhibit the protein activity of glutathione, thioredoxin and Nrf2 gene.
  • the expression inhibitor is an antisense oligonucleotide, siRNA (small interfering RNA), shRNA (Short Hairpin RNA) complementary to the mRNA of the gene or genes that promote the expression of the gene
  • ribozyme ribozyme
  • siRNA that complementarily binds to the mRNA of the glutamate cysteine ligase modifier (GCLM) gene that promotes expression of the glutathione gene is SEQ ID NO: 1 and 2; SEQ ID NOs: 3 and 4; Or a siRNA consisting of the nucleotide sequences of SEQ ID NOs: 5 and 6, and complementarily binding to mRNA of the thioredoxin reductase 1 (TXNRD1) gene, which promotes expression of the thioredoxin gene, SEQ ID NOs: 7 and 8; SEQ ID NOs: 9 and 10; Or consisting of the nucleotide sequence of SEQ ID NO: 11 and 12, siRNA that complementarily binds to the mRNA of the Nrf2 gene is SEQ ID NO: 13 and 14; SEQ ID NOs: 15 and 16; Or a siRNA consisting of the nucleotide sequences of SEQ ID NOs: 17 and 18, wherein the siRNA complementari
  • the activity inhibitor is a compound, peptides, peptide mimetics, substrate analogs, apps that specifically bind to at least one group consisting of glutathione, thioredoxin and Nrf2. It may be any one selected from the group consisting of a tamer and an antibody.
  • the compound specifically binding to glutathione is BSO (buthionine sulfoximine) or NOV-002 (glutathione disulfide mimetic), and the compound specifically binding to thioredoxin is oranopine (auranofin), nitrosourea, or curcumin, and the compound that specifically binds to Nrf2 is trigonelline, chrysin, apigenin, brusatol ), Ascorbic acid or as luteolin.
  • BSO buthionine sulfoximine
  • NOV-002 glutthione disulfide mimetic
  • the compound specifically binding to thioredoxin is oranopine (auranofin), nitrosourea, or curcumin
  • the compound that specifically binds to Nrf2 is trigonelline, chrysin, apigenin, brusatol ), Ascorbic acid or as luteolin.
  • the cancer may be cancer having cisplatin resistance.
  • the cancer is head and neck cancer, lung cancer, stomach cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, scleroderma, ovarian cancer, uterine cancer, cervical cancer, esophageal cancer , Thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, hematologic cancer, lymphoma, psoriasis or fibroadenomas may be selected from the group, but is not limited thereto.
  • the present invention comprises the steps of (a) treating the test substance to cancer cells; (b) confirming that the expression levels of glutathione, thioredoxin, and Nrf2 (nuclear factor (erythroid-derived 2) -like 2) mRNA expression levels or proteins are suppressed. It provides a screening method.
  • the cancer may be cancer having cisplatin resistance.
  • the cancer is head and neck cancer, lung cancer, stomach cancer, liver cancer, colon cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, scleroderma, ovarian cancer, uterine cancer, cervical cancer, esophageal cancer , Thyroid cancer, parathyroid cancer, kidney cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, hematologic cancer, lymphoma, psoriasis or fibroadenomas may be selected from the group, but is not limited thereto.
  • the present invention provides a method for preventing or preventing cancer comprising administering to a subject an inhibitor or activity inhibitor of glutathione, thioredoxin and Nrf2 (nuclear factor (erythroid-derived 2) -like 2) Provide a method of treatment.
  • the method for preventing or treating cancer of the present invention comprises a therapeutically effective amount of the inhibitor or activity inhibitor of glutathione, thioredoxin and Nrf2 (nuclear factor (erythroid-derived 2) -like 2) of the present invention.
  • Administering to the subject can be determined by the specific composition, including the type and severity of the reaction to be achieved, whether or not other agents are used in some cases, the age, weight, general health, sex and diet, time of administration, It is desirable to apply differently depending on the route of administration and the rate of release of the composition, the duration of treatment, and the various factors and similar factors well known in the medical arts, including drugs used with or concurrent with the specific composition. Therefore, the effective amount of the composition suitable for the purpose of the present invention is preferably determined in consideration of the above matters.
  • the subject is applicable to any mammal, and the mammal includes humans and primates, as well as domestic animals such as cattle, pigs, sheep, horses, dogs, and cats.
  • Expression inhibitors or activity inhibitors of glutathione, thioredoxin, and Nrf2 inhibit the growth of apoptosis resistant cancer cells and apoptosis By inducing it can be usefully used for the treatment of cancer.
  • FIG. 1 shows the results of apoptosis-inducing effects of cisplatin-sensitive and cisplatin-resistant HNC cells on GSH inhibitor BSO (buthionine sulfoximine) and Trx inhibitor oranopine.
  • A shows the apoptosis effect on oranopine according to the concentration
  • B shows the apoptosis effect by BSO according to the concentration
  • C shows the apoptosis effect by BSO and oranopine
  • D shows the apoptosis effect by BSO and oranopine in different types of HNC cell lines and SNU cell lines.
  • FIG. 2 shows the results of ROS (reactive oxygen species) induction and apoptosis effects in HNC cells against BSH (buthionine sulfoximine) and Trx inhibitor oranopine.
  • A is a result of comparing the survival rate of HNC cells after treatment with BOS, oranopine or BSO- oranopine
  • B is a result of observing HNC cells under a microscope
  • C is BOS, oranopine or The results of measurement of the amount of ROS in each group treated with BSO-oranopine and not treated with or without the antioxidant Trolox
  • D is the result of measuring the cell viability under the condition (C) (* P ⁇ 0.01; and ** P ⁇ 0.001).
  • FIG. 3 shows the suboptimal effect of apoptosis in resistant HNC cells by inhibition of GSH and Trx.
  • A GCLM or TXNRD1 It was a result of transducing the mRNA expression level of GSH or TrxR by transducing the siRNA of the gene, respectively
  • B is the analysis of the amount of GSH in the cell after introducing the siRNA of the gene
  • C is the siRNA of the gene Analysis of TrxR activity after introduction
  • D is GCLM And / or TXNRD1
  • the relative cell numbers were measured after treatment of BSO, oranopine, or BSO-oranopine in HN3 and HN3-cisR cells into which siRNAs were introduced.
  • E shows apoptosis by Annexin-V and PI staining. It is the result of analysis (* P ⁇ 0.05 in A to D; and * P ⁇ 0.01, ** P ⁇ 0.05, *** P ⁇ 0.01 in E).
  • Figure 4 shows the results for the induction of Nrf2-ARE activity by BSO and oranopine.
  • A is the result of confirming the protein expression levels of Nrf2, Keap1, NQO1 and HO-1 by Western blotting after treatment of HOS3 or HN3-cisR cells with BOS, oranopine or BSO-oranopine, and
  • B NFE2L2 And HMOX1 After transducing siRNAs for genes into HN3-cisR cells, it was confirmed whether mRNA of each gene was inhibited, and
  • C is NFE2L2.
  • siRNAs si GCLM , si TXNRD1 , respectively
  • si GCLM si GCLM , si TXNRD1 , respectively
  • NFE2L2 HMOX1 SiRNA for si siFE2L2
  • si HMOX1 si HMOX1
  • D is NFE2L2.
  • SiRNA (si NFE2L2 ) for the gene was transduced into HN3-cisR cells and then treated with BSO, oranopine, trolox or a combination thereof, and the results were shown for apoptosis effect through Annexin-V and PI staining (B , * P ⁇ 0.05 in C; and * P ⁇ 0.01 in D, ** P ⁇ 0.05, *** P ⁇ 0.05).
  • NFE2L2 And HMOX1 SiRNA for the gene was transduced into HN3-cisR cells and treated with BSO, oranopine or BSO-oranopine to measure cell viability, and
  • B shows BSO, oranopine or BSO- in HN3-cisR cells.
  • Cell counts were measured after further treatment of oranopine with trigonelin.
  • C shows the amount of ROS after treatment of trigonellin and / or Trolox with BSO, oranopine, or BSO-oranopine in HN3-cisR cells.
  • D is the result of measuring the apoptosis effect after Annexin V and PI staining (* P ⁇ 0.05, ** P ⁇ 0.01 in A; and * P ⁇ 0.05, ** in B to D) P ⁇ 0.01).
  • Figure 6 is a result showing the growth inhibitory effect after tumor transplantation by BSO, oranopine and trigonelin.
  • A is the result of measuring the volume of the tumor after treatment with BSO, oranopine, trigonelin or a combination thereof
  • B is the result of weighing the tumor
  • C is twice a week of each mouse Body weight is measured
  • D is the result of measuring TUNEL-positive killer cells (* P ⁇ 0.05, ** P ⁇ 0.01).
  • FIG. 7 shows that malignant tumor cells of resistance by blocking the GSH, Trx and Nrf2 antioxidant pathways can be targeted.
  • Figure 8 shows the results of confirming the protein expression amount for each gene after the introduction of siRNA for the GCLM , TXNRD1 and NFE2L2 gene in HN3-cisR cells.
  • Figure 9 shows the results confirmed by Western blotting the amount of Nrf2 expression in cisplatin-sensitive or resistant HNC cells.
  • FIG. 11 shows the results of the next cell apoptosis effect by GSH and Trx inhibition.
  • A shows the apoptosis effect by Annexin V and PI staining after treatment with BSO, oranopine, Trolox or a combination thereof in HN9 and HN9-cisR cells
  • B HN9 transduced with si NFE2L2 After treatment with BSO, oranopine, Trolox, or a combination thereof in -cisR cells, apoptosis was shown by Annexin V and PI staining.
  • FIG 13 shows mice with tumors treated with control (A) and BSO- oranopine-trigonelline (B).
  • Figure 14 is the result of comparing the degree of tissue damage in the control and the treatment of BSO- oranopine-trigonelin.
  • Figure 15 shows the results of microscopic analysis of TUNEL-positive killing cells in the tumor section of the control group (A) and BSO- oranopine-trigonelin (B) treated group.
  • FIG. 16 shows the results of measuring the amount of GSH in cells in tumor tissues of mice treated with BSO, oranopine, trigonelin, or a combination thereof (** P ⁇ 0.01).
  • 17 is a result of apoptosis induction effect in lung cancer cells (H460 and H2009) and ovarian cancer cells (OVCAR3 and SKOV3) after treatment with BSO, oranopine or a combination thereof.
  • FIG. 18 shows the results of apoptosis induction effects in lung cancer cells (H2009) and ovarian cancer cells (OVCAR3) after treatment with BSO, oranopine, trigonelin, or a combination thereof (* P ⁇ 0.05 and ** P ⁇ 0.01) .
  • “Pharmaceutical composition” refers to a mixture or solution containing one or more therapeutic agents administered to a subject, eg, a mammal or a human, to prevent or treat a particular disease or condition in which the mammal suffers. .
  • the "pharmaceutical composition” according to the present invention is an expression capable of inhibiting one or more of each or simultaneously a crowd consisting of glutathione, thioredoxin and Nrf2 (nuclear factor (erythroid-derived 2) -like 2) It may be an inhibitor or an activity inhibitor.
  • expression inhibitors of glutathione, thioredoxin, and Nrf2 may bind to or simultaneously complement each of the gene mRNAs or express the genes. It may be any one selected from the group consisting of antisense oligonucleotides, small interfering RNA (siRNA), short hairpin RNA (shRNA), and ribozyme that complement or bind to each of the mRNAs of the gene promoting the It is not limited thereto.
  • siRNA refers to a short double-chain RNA capable of inducing RNA interference (RNAi) through cleavage of a specific mRNA. It consists of a sense RNA strand having a sequence homologous to the mRNA of the target gene and an antisense RNA strand having a sequence complementary thereto. Since siRNA can inhibit the expression of a target gene, it is provided by an efficient method of knocking down or by gene therapy.
  • RNAi RNA interference
  • antisense oligonucleotide encompasses a nucleic acid-based molecule having a complementary sequence to a target miRNA, in particular, a miRNA leader sequence, thereby forming a duplex with the miRNA.
  • a target miRNA in particular, a miRNA leader sequence
  • antisense oligonucleotide can be described herein as a "complementary nucleic acid-based inhibitor.”
  • the term "complementary" means that the antisense oligonucleotides are sufficiently complementary to selectively hybridize to a miR-BART1-3p target under certain hybridization or annealing conditions, preferably physiological conditions, and are substantially complementary. It has the meaning encompassing both substantially complementary and perfectly complementary, and preferably means completely complementary.
  • the inhibitors of glutathione, thioredoxin and Nrf2 are specific to glutathione, thioredoxin and Nrf2. It may be any one selected from the group consisting of compounds, peptides, peptide mimetics, substrate analogs, aptamers and antibodies that bind to, but is not limited thereto.
  • prevention means any action that inhibits or delays the onset of cancer by administration of a pharmaceutical composition according to the present invention.
  • treatment means any action in which symptoms caused by cancer are improved or beneficially altered by administration of the pharmaceutical composition according to the present invention.
  • the pharmaceutical composition according to the invention may comprise a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carriers are conventionally used in the preparation, and include, but are not limited to, saline solution, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, and the like. If necessary, other conventional additives such as antioxidants and buffers may be further included.
  • diluents, dispersants, surfactants, binders, lubricants and the like may be additionally added to formulate injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
  • Suitable pharmaceutically acceptable carriers and formulations may be preferably formulated according to each component using the methods disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA.
  • the pharmaceutical composition of the present invention is not particularly limited in formulation, but may be formulated as an injection, inhalant, or external skin preparation.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, skin, nasal, airways) according to the desired method, and the dosage is determined by the condition and weight of the patient, Depending on the extent, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.
  • composition according to the invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level means the type, severity, and activity of the patient's disease. , Drug sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical arts.
  • the composition according to the present invention may be administered as a separate therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.
  • the term "combination administration” is defined to include administering a selected therapeutic agent to a single patient, and is intended to include therapeutic regimens in which the agents do not necessarily have to be administered in the same route of administration or simultaneously.
  • the effective amount of the composition according to the present invention may vary depending on the age, sex, and weight of the patient, and generally 0.001 to 150 mg, preferably 0.01 to 100 mg daily or every other day or 1 day per kg of body weight It can be administered in 1 to 3 divided doses.
  • the dosage may be increased or decreased depending on the route of administration, the severity of obesity, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
  • the term “subject” or “patient” includes an animal that may or may suffer from cancer or any disorder directly or indirectly involved in cancer.
  • subjects include mammals such as humans, dogs, cattle, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals.
  • the subject is a human, eg, a human suffering from, at risk of suffering from cancer, or potentially suffering from cancer.
  • the term “synergy” or “synergy” refers to (a) an inhibitor of glutathione, (b) an inhibitor of thioredoxin, and (c) a nuclear factor (Nrf2). This means that the effects of using an inhibitor of (erythroid-derived 2) -like 2) alone are greater than the sum of them.
  • this synergy provides greater efficacy at the same or lower doses.
  • the determination of the expression level can be measured at the level of transcription (nucleic acid) product using methods known in the art.
  • mRNA can be quantified using probes by hybridization methods (eg, Northern blot analysis).
  • the probe may be labeled with appropriate materials such as dyes, fluorescent materials, and isotopes, and the expression level or function may be detected as the detection intensity of the hybridized label.
  • the transcription products of the genes of the invention can be quantified using primers by amplification-based detection methods (eg RT-PCR).
  • the primer can be prepared based on the available sequence information of the gene.
  • the expression level measurement in the present invention can be measured at the translation (protein) product level.
  • Methods for measuring the amount of the protein include all immunoassay methods known in the art, such as immunoprecipitation, western blot, immunohistochemical analysis using an antibody that specifically recognizes the protein.
  • the antibody may be monoclonal or polyclonal.
  • any fragment or modification of an antibody eg, chimeric antibody, scFv, Fab, F (ab ') 2, Fv, etc.
  • any fragment or modification of an antibody eg, chimeric antibody, scFv, Fab, F (ab ') 2, Fv, etc.
  • HNC head and neck cancer
  • HN3-cisR, HN4-cisR and HN9-cisR three cisplatin-resistant HNC cell lines, which were developed from HN3, HN4 and HN9, respectively, through continuous exposure to increased cisplatin concentrations.
  • IC50 (half-maximal inhibitory concentrations) values of cisplatin (Sigma-Aldrich, St. Louis, MO, USA) were determined by cell viability assay, 2.2-3.5 ⁇ M in parental cells, and 25.5 ⁇ in cisplatin-resistant HNC cells. 38.9 ⁇ .
  • MTT assay was performed with tetrazolium compound MTT (3- [4,5-dimethyl-2-thiazolyl] -2,5-diphenyl-2H-tetrazolium bromide; Sigma-Aldrich) for 4 hours and in solubilization buffer for 2 hours. After loading, the absorbance was measured at 570 nm using a SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, Calif., USA).
  • Trypan blue exclusion was performed with 0.4% trypan blue staining and counted using a hemocytometer.
  • Apoptosis assays were performed by annexin V (Sigma-Aldrich) and PI (propidium iodide; Sigma-Aldrich) staining, flow cytometry and Cell Quest Pro software (BD Biosciences, Franklin Lakes, NJ). , USA) were used to count annexin V or PI positive cells. All assays were performed three times and three times.
  • the CI (combination index) of drug action was calculated using the Chou-Talalay method, and "CI ⁇ 1" was considered synergistic (Chou TC. Cancer Res 70: 440-6, 2010).
  • Glutathione glutathion : GSH
  • ROS reactive oxygen species
  • Trx thioredoxin
  • GSH levels in lysates of HNC cells were measured using a GSH colorimetric detection kit (BioVision Inc., Milpitas, CA, USA) after exposure to other drugs for 24 hours.
  • ROS production of cells in supernatants of differently treated HNC cell lysates for 24 hours was measured using DCF-DA (2 ', 7'-dichlorofluorescein diacetate; Enzo Life Sciences, Farmingdale, NY, USA). ROS amounts were analyzed with a FACSCalibur flow cytometer equipped with CellQuest Pro (BD Biosciences). Trx activity was measured using Trx activity fluorescent assay kit (Cayman Chemical, Ann Arbor, MI, USA) after treatment with HNC cells for 24 hours.
  • Cisplatin-resistant HN3 for silencing GCLM glutthione; gene that promotes GSH expression
  • TXNRD1 thioreodoxin reductase-1, TrxR1
  • NFE2L2 Nrf2
  • HMOX1 heme oxygenase 1; HO1
  • siRNA-induced gene inhibition was performed by reverse blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) from 1-2 ⁇ g total RNA for each sample using Western blotting and the SuperScript® III RT-PCR system (Thermo Fisher Scientific). was performed.
  • RT-qPCR reverse transcription-quantitative polymerase chain reaction
  • GSH Forward Reverse GCLM
  • IDTDNA Integrated DNA Technologies, Coralville, IA, USA
  • Tumor size and weight of each mouse were measured twice a week and volume was calculated as (length ⁇ width 2 ) / 2. Mice were sacrificed on day 25 and tumors were isolated and analyzed by GSH measurement of cells. Arbitrary fluorescence units (AFUs) were compared to tumors treated differently.
  • AFUs Arbitrary fluorescence units
  • BSOs acted as a photosensitizer for oranopine-induced apoptosis, and inhibition of the GSH and Trx system may induce cancer cell death.
  • GSH is reported to be synthesized by glutamate cysteine ligase (GCL) with a glutamate cysteine ligase modifier (GCLM) and a glutamate cysteine ligase catalytic (GCLC) subunit
  • GCL glutamate cysteine ligase
  • GCLM glutamate cysteine ligase modifier
  • GCLC glutamate cysteine ligase catalytic subunit
  • TXNRD1 is the gene of Thioredoxin reductase 1. Inhibition of the GCLM and TXNRD1 genes was found to induce GSH depletion and Trx activity inhibition, respectively (FIGS. 3A, 3B, 3C and 8).
  • the double-blocking system of GSH and Trx was found to be synergistic in inducing the death of cisplatin-folk and cisplatin-resistant cells (FIGS. 3D and 3E).
  • some of the cisplatin-resistant HNC cells, such as HN3-cisR and HN9-cisR showed suboptimal effects, ie, some cell death was not inhibited (FIGS. 1C and 9).
  • Nrf2 nuclear factor (erythroid-derived 2) -like 2) and NQO1 (NAD (P) H quinone oxidoreductase 1) and HO-1 (Heme oxygenase 1). It was found to increase the expression of the containing antioxidant response element (ARE) pathway (FIG. 4A), and accordingly, siRNAs of the GCLM gene for inhibiting GSH synthesis and the siRNAs of TXNRD1 gene for suppressing Trx synthesis (si GCLM , respectively ) .
  • si TXNRD1 ) transduced HNC cells were used for the inhibition of NFE2L2 (Nrf2) or HMOX1 gene, or the pharmaceutical inhibition of Nrf2 by trigonelin.
  • Nrf2 silencing prevented time-dependent increase in Nrf2 induced by BSO and oranopine (FIG. 11).
  • BSOs act as photosensitizers for other drugs, showed biocompatibility in tissues in vivo , and inhibited the growth of cisplatin-resistant cancer cells by blocking GSH, Trx and Nrf2 systems. .
  • Example 6 Apoptosis effect in lung and ovarian cancer
  • the present inventors confirmed whether or not induction of apoptosis in lung cancer and ovarian cancer cells by combined treatment of BSO and oranopine.
  • Lung cancer cells H460 and H2009
  • ovarian cancer cells OVCAR3 and SKOV3
  • death of lung cancer and ovarian cancer cells occurred more significantly in the group treated with the combination of BSO and oranopine than when only BSO alone was treated (CI ⁇ 1.0; FIG. 17).
  • the present inventors performed experiments to determine whether the treatment of the BSH, oranopine and trigonelin induce apoptosis in order to determine the triple blocking effect of the GSH, Trx and Nrf2 system in lung cancer and ovarian cancer cells.
  • Trig 100 ⁇ M
  • BSO + Oranopine + Trigonelin Trigonelin
  • the survival rate was confirmed.
  • the combination of BSO and oranopine had an effect of inducing apoptosis, and the combination of BSO, oranopine and tri

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pour prévenir ou traiter le cancer, la composition comprenant comme principe actif un inhibiteur de l'expression, ou un inhibiteur de l'activité, du glutathion, de la thiorédoxine et du Nrf2. En particulier, dans le cas de cancers présentant une résistance au cisplatine, la composition inhibe l'expression du gène, ou inhibe l'expression ou l'activité de la protéine, et peut donc être utilisée utilement pour prévenir ou traiter un cancer résistant au cisplatine.
PCT/KR2017/004963 2016-12-20 2017-05-12 Induction sélective de l'apoptose du cancer par inhibition combinée du glutathion, de la thiorédoxine et de l'antioxydant nrf2 WO2018117345A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160174698A KR101908029B1 (ko) 2016-12-20 2016-12-20 Glutathione, Thioredoxin, Nrf2 항산화계 병합억제를 통한 선택적 암세포사멸 유도
KR10-2016-0174698 2016-12-20

Publications (1)

Publication Number Publication Date
WO2018117345A1 true WO2018117345A1 (fr) 2018-06-28

Family

ID=62626762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/004963 WO2018117345A1 (fr) 2016-12-20 2017-05-12 Induction sélective de l'apoptose du cancer par inhibition combinée du glutathion, de la thiorédoxine et de l'antioxydant nrf2

Country Status (2)

Country Link
KR (1) KR101908029B1 (fr)
WO (1) WO2018117345A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110438126A (zh) * 2019-06-18 2019-11-12 武汉市农业科学院 一种抑制Nrf2基因表达的siRNA序列及其反应体系
WO2021014812A1 (fr) * 2019-07-24 2021-01-28 国立大学法人東海国立大学機構 Traitement pour une tumeur fibroblastique ou myofibroblastique et une maladie
WO2023051088A1 (fr) * 2021-10-01 2023-04-06 浙江中医药大学 Utilisation de la dihydrotanshinone i dans la préparation d'un inhibiteur de nrf2

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054073A1 (fr) * 2022-09-07 2024-03-14 재단법인 아산사회복지재단 Biomarqueur pour diagnostiquer une résistance à la préchimiothérapie chez des patients atteints d'un cancer solide et procédé pour fournir des informations afin de diagnostiquer une résistance à la préchimiothérapie l'utilisant
CN115804829B (zh) * 2022-11-11 2023-12-12 广州国家实验室 S-亚硝基化谷胱甘肽还原酶抑制剂在改善肺纤维化血管新生中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255117A1 (en) * 2007-04-06 2010-10-07 The Johns Hopkins University Methods and compositions for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255117A1 (en) * 2007-04-06 2010-10-07 The Johns Hopkins University Methods and compositions for the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENHAR: "Dual targeting of the thioredoxin and glutathione systems in cancer and HIV", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 5, 2 May 2016 (2016-05-02), pages 1630 - 1639, XP055605777, ISSN: 0021-9738, DOI: 10.1172/JCI85339 *
LV ET AL.: "Inhibition of heme oxygenase-1 enhances the chemosensitivity of laryngeal squamous cell cancer Hep-2 cells to cisplatin", APOPTOSIS, vol. 21, no. 4, 22 January 2016 (2016-01-22), pages 489 - 501, XP035635732, ISSN: 1360-8185, DOI: 10.1007/s10495-016-1216-7 *
NO ET AL.: "Targeting Nrf2 signaling to combat chemoresistance", JOURNAL OF CANCER PREVENTION, vol. 19, no. 2, 30 June 2014 (2014-06-30), pages 111 - 117, XP055605769, ISSN: 2288-3649, DOI: 10.15430/JCP.2014.19.2.111 *
ROH: "Targeting of the glutathione, thioredoxin, and Nrf2 antioxidant systems in head and neck cancer", ANTIOXIDANTS & REDOX SIGNALING, vol. 27, no. 2, 14 November 2016 (2016-11-14), pages 106 - 114, XP055605790, ISSN: 1523-0864, DOI: 10.1089/ars.2016.6841 *
SAMATIWAT: "Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 388, no. 6, 24 February 2015 (2015-02-24) - June 2015 (2015-06-01), pages 601 - 612, XP055605786, ISSN: 0028-1298, DOI: 10.1007/s00210-015-1101-x *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110438126A (zh) * 2019-06-18 2019-11-12 武汉市农业科学院 一种抑制Nrf2基因表达的siRNA序列及其反应体系
WO2021014812A1 (fr) * 2019-07-24 2021-01-28 国立大学法人東海国立大学機構 Traitement pour une tumeur fibroblastique ou myofibroblastique et une maladie
WO2023051088A1 (fr) * 2021-10-01 2023-04-06 浙江中医药大学 Utilisation de la dihydrotanshinone i dans la préparation d'un inhibiteur de nrf2

Also Published As

Publication number Publication date
KR20180071722A (ko) 2018-06-28
KR101908029B1 (ko) 2018-10-15

Similar Documents

Publication Publication Date Title
WO2018117345A1 (fr) Induction sélective de l'apoptose du cancer par inhibition combinée du glutathion, de la thiorédoxine et de l'antioxydant nrf2
Guo et al. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis
KR20100102637A (ko) 토포이소머라제 억제제 및 ｐａｒｐ 억제제의 병용물에 의한 암의 치료
US20140187495A1 (en) Methods for treating glioblastoma
WO2019083971A1 (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de lsd1 en combinaison avec une immunothérapie
US12083113B2 (en) Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients
WO2020159171A2 (fr) Composition comprenant de la streptonigrine et un agent anticancéreux pour prévenir ou traiter le cancer colorectal
US20230090446A1 (en) Antisense oligonucleotide targeting linc00518 for treating melanoma
WO2013134546A1 (fr) Procédés et matériaux pour traiter le cancer
US20150190484A1 (en) Methods for reducing cellular senescence mediated by dna damaging agents
WO2020080861A1 (fr) Composition de traitement du cancer gastrique comprenant un inhibiteur de syt11 en tant qu'ingrédient actif
EP3793544B1 (fr) Compositions bifonctionnelles pour le traitement du cancer
US9963701B2 (en) Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
WO2014025837A1 (fr) Méthodes de traitement et de prévention de tauopathies par l'inhibition de récepteurs de l'endothéline
WO2011087343A2 (fr) Composition destinée à traiter un cancer lié à une infection par un papillomavirus humain
US20220347125A1 (en) Antitumor agent and compounding agent
WO2021002664A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un cancer
EP4175644A1 (fr) Combinaison d'antibiotiques anti néoplasiques et d'inhibiteurs de bcl-2 pour le traitement de la leucémie myéloïde aiguë (lma) entraînée par npm-1
KR101859641B1 (ko) 아르테미신 유도체 및 Nrf2 억제제를 포함하는 항암용 조성물
US11045456B2 (en) Compositions and methods for treating COPD and other inflammatory conditions
WO2023075123A1 (fr) Composition pharmaceutique destinée au traitement et à l'inhibition de métastases du cancer colorectal, comprenant des miarn, et son utilisation
WO2023075122A1 (fr) Composition pharmaceutique pour le traitement et l'inhibition de métastases du cancer colorectal et son utilisation
US20230414749A1 (en) Use of immune checkpoint inhibitors in combination with anti-aging drugs in preparation of tumor treatment products
WO2020241816A1 (fr) Nouvel agent thérapeutique contre les cancers digestifs, et méthode de criblage associée
US20220347180A1 (en) Enhancing cancer therapy treatment with bh3 mimetics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17884313

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17884313

Country of ref document: EP

Kind code of ref document: A1